What is Palynziq, and what did the FDA approve?
Palynziq (pegvaliase-pqpz) is an FDA-approved treatment for adults with phenylketonuria (PKU) who have uncontrolled blood phenylalanine levels despite available treatments. Its approval is for use in adults with PKU, not for children or for general PKU management without uncontrolled disease. [1]
When was Palynziq approved by the FDA?
Palynziq received FDA approval in 2018. [1]
What conditions does Palynziq treat (and who is eligible)?
FDA labeling specifies adult patients with phenylketonuria (PKU) with uncontrolled phenylalanine levels despite existing PKU therapies. [1]
How is Palynziq administered?
Palynziq is given as an injection (subcutaneous dosing). [1]
What are the major risks patients ask about after FDA approval?
The most prominent FDA safety focus around Palynziq is hypersensitivity/anaphylaxis and injection-related reactions, which is a key part of how the drug’s use is managed in practice. [1]
How does Palynziq work compared with standard PKU therapies?
Unlike dietary restriction or sapropterin (which can help some patients), Palynziq uses pegylated enzyme therapy (pegvaliase) to break down phenylalanine, aiming to lower blood phenylalanine in adults whose PKU remains uncontrolled despite other options. [1]
What happens after FDA approval—availability and access?
After FDA approval, Palynziq becomes available through standard U.S. distribution, with use guided by the FDA-approved indication and prescribing information (including safety monitoring and dose management). [1]
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761186